Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

University of Bristol Scientists Form Halo Therapeutics to Develop ‘Pan-Corona’ Antivirals

by Global Biodefense Staff
April 15, 2021
University of Bristol Scientists Form Halo Therapeutics to Develop ‘Pan-Corona’ Antivirals

SARS-CoV-2 virus particles (UK B.1.1.7 variant). Credit: NIAID

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for coronavirus.

Bristol-based Halo Therapeutics is founded by the team of leading scientists who found that exposing the SARS-CoV-2 virus to a free fatty acid called linoleic acid locks the virus’s spike protein into a closed, non-infective form, stopping it in its tracks.

The company is now preparing to make an application to start clinical trials. If proven effective, the antivirals could be used by people of all ages worldwide at the first sign of COVID-19 symptoms, or if they have been in contact with someone with the virus, preventing the virus from taking hold and stopping further transmission.

“The aim of our treatment is to significantly reduce the amount of virus that enters the body and to stop it from multiplying. Then, even if people are infected with the virus or exposed to it, they will not become ill because the antiviral prevents the virus from spreading to the lungs and beyond. Importantly, because the viral load will be so low it will likely also stop transmission,” explained Professor Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology at Bristol and one of the team leading the drug’s development.

Lab studies indicate the antiviral will work against all pathogenic coronavirus strains including the highly contagious ‘UK (Kent)’, ‘South African’ and ‘Brazilian’ variants by preventing the virus from penetrating cells in the nose, throat and lungs.

The treatments under development by Halo Therapeutics include a nasal spray and an asthma-type inhaler, and offer the possibility of a game-changing pan-coronavirus antiviral to treat patients at all stages of the disease and to reduce the transmission of the virus.

Tags: AntiviralsClinical TrialsDrug DevelopmentEditor Pick

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States
Industry News

Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States

September 7, 2022
Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response
Industry News

Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

August 31, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy